Drug Pricing
Expert articles and analysis related to drug pricing.
AI Summary — Last 7 Days
Drug-pricing pressure is converging on CMS payment-model policy: midsize biotechs are lobbying the White House and HHS to halt two pending CMS pricing models they argue would undermine R&D and commercial viability, while CMS is moving ahead with draft guidance for the 2028 Medicare Drug Price Negotiation cycle—signaling continued Trump administration interest in using Medicare purchasing power despite industry pushback (Endpoints News, AHA). At the same time, Congress is advancing bipartisan drug-cost
Related Articles
The Drug Changing Medicine
By EMANUEL SARKEES The United States is in the middle of what researchers are calling one of the most significant pharmacological developments in modern medicine. GLP-1 receptor agonists, the drug cla...
Medicaid MFN Pricing Could Save $8.6 Billion
Draft guidance released for 2028 cycle of Medicare drug price negotiations
Draft guidance released for 2028 cycle of Medicare drug price negotiations American Hospital Association
Midsize biotechs press White House to drop CMS pricing rules
A number of midsize biotech companies have met with White House and HHS officials in the last week, presenting their case for why two pending CMS pricing models could hinder their business and should ...
The price of Ozempic is a meaningless phrase
By JOHN SAMARAS Ask what Ozempic costs. The honest answer runs from $25 a month to $1,100 a month, and every number in that range is real, published, and defensible. A phraseContinue reading...
TrumpRx at 6 months: Has the drug-pricing experiment delivered?
TrumpRx at 6 months: Has the drug-pricing experiment delivered? Becker's Hospital Review
PBMs pitch bolder ways to rein in employer drug costs
PBMs pitch bolder ways to rein in employer drug costs Modern Healthcare
Legislation Advances to Lower Drug Costs and Enhance Federal Oversight
Legislation Advances to Lower Drug Costs and Enhance Federal Oversight HCI Innovation Group
Court rules that companies may not impose 340B rebate model without HHS approval
Court rules that companies may not impose 340B rebate model without HHS approval American Hospital Association
STAT+: Rare disease drugmakers try to avoid Trump price cuts
Plus, GOP voters want a crackdown on health care fraud, and how PBMs are skirting state laws.